Featured Jobs

Associate Attorney - Tax (Honolulu HI)

Free Daily News and Jobs

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Get the BenefitsLink app LinkedIn

By Date   |   By Company Name

View More Press Releases by NovaSom, Inc.

Press release:

NovaSom Announces Appointment of Ron Loeppke, MD to Board of Directors

Issued by: NovaSom, Inc.

Date: July 19, 2012

NovaSom Announces Appointment of Ron Loeppke, MD to Board of Directors

National Expert in Preventive and Occupational Healthcare to Guide Initiative to Address the Impact of Sleep Apnea for the Employer Community

GLEN BURNIE, Md.--NovaSom, Inc., the leader in home sleep testing and cost-saving solutions for Obstructive Sleep Apnea (OSA) management, announces the appointment of Ron Loeppke, MD to its Board of Directors. Dr. Loeppke is a national expert in preventive and occupational health, and in his new role will offer strategic guidance to NovaSom as it partners with employers to increase diagnosis and treatment of OSA, a condition that affects over 40 million Americans.

Richard Hassett, MD, CEO, NovaSom, said, “Dr. Loeppke is a terrific addition to our Board as we enhance our focus on working with employers on the early detection of OSA, one of the most serious and underdiagnosed conditions in the U.S. He has a strong track record of helping deliver chronic condition and population health management services that improve health outcomes while reducing healthcare costs. Employers large and small today are aiming to optimize their sleep diagnosis and therapy continuum to achieve more present, productive employees while carefully managing the spend in this area.”

Dr. Loeppke has over 30 years of clinical and executive experience in preventive medicine and managing health issues in the workplace. He currently serves as Vice-Chairman of U.S. Preventive Medicine, a company focused on preventive healthcare to improve health and reduce costs. Prior, Dr. Loeppke held executive roles at organizations including Alere Medical and PHYCOR, Inc., where he worked directly with employers and health plans on initiatives to enhance employee health and productivity.

Dr. Loeppke is board-certified in Preventive Medicine and fellowship-trained in Occupational Medicine, and practiced as an occupational and preventive health physician from 1984 to 1994. He is a Fellow of both the American College of Preventive Medicine and American College of Occupation and Environmental Medicine (ACOEM). Dr. Loeppke is also on the Board of Directors as well as the President-elect of ACOEM. In addition, he is the Chairman of the Diabetes at Work group of the Center for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) National Diabetes Education Program. Dr. Loeppke has authored numerous research articles related to employer health and productivity, occupational health and wellness, managed care, and innovative healthcare delivery, most recently in the Journal of Occupational and Environmental Medicine, June 2011.

Dr. Loeppke said, “I am honored to be joining the NovaSom board and look forward to working with the management team to help provide employers with education and access to cost-effective, convenient home sleep testing for sleep apnea as a critical step towards improving health for millions of Americans. Employers bear much of the burden of escalating healthcare costs, and empowering them with the tools to directly diagnose and treat serious diseases such as sleep apnea, which is associated with a host of other dangerous health conditions, is a compelling preventive care model for the future.”

NovaSom’s sleep testing technology directly measures the parameters recommended by the American Academy of Sleep Medicine to diagnose OSA, and has been proven clinically equivalent to traditional polysomnography in two peer-reviewed publications. For more information about NovaSom and its home sleep testing technology, please visit www.NovaSom.com.

About OSA

Obstructive Sleep Apnea (OSA) affects 40 million Americans, of which 18 million have moderate to severe disease. Of these, a startling 85% of sufferers are undiagnosed and therefore untreated, generating significant medical expense for patients and the healthcare system. Nearly half of all OSA patients also suffer from one or more serious health conditions such as diabetes, hypertension or heart failure that is either aggravated or caused by OSA. Treating OSA reduces medical expenses, improves patient quality of life and lowers associated health risks.

About NovaSom, Inc.

NovaSom, Inc. is the market leader in Obstructive Sleep Apnea (OSA) home testing, with the first FDA-cleared system, NovaSom® Home Sleep Test, and the second generation AccuSom® Home Sleep Test, the first and only FDA-cleared wireless HST. The NovaSom home sleep testing technology and MediTrack® portal have been shown to provide in-home, clinically equivalent diagnosis of OSA at a significantly reduced cost as compared to in-facility testing for uncomplicated, adult OSA. NovaSom’s home sleep tests are currently covered for more than 165 million U.S. lives, through partnerships with major health insurers.

NovaSom also offers comprehensive service programs that are utilized by payers, employers, primary care and sleep specialist physicians nationwide, that enable significant cost savings for OSA management. In an effort to combat the growing OSA epidemic, NovaSom also partners with sleep centers, enabling sleep specialists to offer clinically appropriate patients an alternative, convenient testing option, expanding access to diagnosis and treatment.

NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center and Telehealth Provider and is approved by CMS as an Independent Diagnostic Testing Facility. For more information, visit www.NovaSom.com.

For more information: http://www.marketwatch.com/story/novasom-announces-appointment-of-ron-loeppke-md-to-board-of-directors-2012-07-09

View More Press Releases by NovaSom, Inc.

This is a press release issued by the company named above. BenefitsLink is not the author. Use of any information obtained from this release is voluntary, and reliance on it should only be undertaken after an independent review of its accuracy, completeness, efficacy, and timeliness. Reference to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer, or otherwise does not constitute or imply endorsement, recommendation, or favoring by BenefitsLink.

© 2019 BenefitsLink.com, Inc.